You are here: Industry Insights > Ingelheim

News List

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors drugs
June 19, 2019
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors.
Boehringer Ingelheim announces finalists of the Making More Health Accelerator Program worldpharmanews
May 15, 2019
Boehringer Ingelheim announces finalists of the Making More Health Accelerator Program.
AMAL Therapeutics Enters Clinical Collaboration with Boehringer Ingelheim to Evaluate ATP128 in Combination with BI754091 b3cnewswire
May 05, 2019
AMAL Therapeutics Enters Clinical Collaboration with Boehringer Ingelheim to Evaluate ATP128 in Combination with BI754091.
Boehringer Ingelheim enhances oncology R&D with novel MacroDel delivery technology via acquisition of ICD Therapeutics worldpharmanews
April 10, 2019
Boehringer Ingelheim enhances oncology R&D with novel MacroDel delivery technology via acquisition of ICD Therapeutics...
New tablet production facility in Ingelheim: Centerpiece for global launches worldpharmanews
September 04, 2018
Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on development activities for drugs in tablet form and manufacture them for worldwide ma
Boehringer Ingelheim Bolsters Biologics R&D contractpharma
July 03, 2018
Boehringer Ingelheim has unveiled plans to invest €230 million into a new Biologicals Development Center (BDC) at the company's research and development site in Biberach, Germany during the foundation stone laying for the new center.
Boehringer Ingelheim Strikes a Series of Investments and Collaborations Worldwide biospace
April 13, 2018
The last week has marked plenty of investment activity in operations, collaborations and PR the last week or two for Ingelheim, Germany-based Boehringer Ingelheim.